An Alzheimer’s disease diagnosis may come with considerable uncertainty for the person affected and their family. Dr. Alma Ghirelli highlights the vital role of clinicians in providing clear guidance to help them plan ahead and access appropriate care.¹,²

Brain changes in dementia can start long before symptoms appear. Prof. Hisatomo Kowa explains how targeted prevention through lifestyle changes, cognitive and social engagement, and multifactorial risk management may lower dementia risk.¹⁻³ #AlzheimersAwareness

CTAD 2025 highlights progress across Alzheimer’s disease research and diagnosis. In your view, which area holds potential to help transform future clinical practice and patient care?

Dr. Atsushi Iwata explores the concept of cognitive resilience, which involves three elements: cognitive reserve, brain reserve, and active brain maintenance. Can a deeper understanding of resilience guide new strategies for prevention in Alzheimer’s disease? ¹,²

Just 7 days until #CTAD25 kicks off! This annual meeting in Alzheimer’s disease research brings together the community for data-driven dialogue and collaboration to advance clinical progress. Lilly is proud to join as a platinum sponsor. See you there! #TimeIsNowAD

#CTAD 2025 is where data, dialogue, and discovery meet. Experts in Alzheimer’s disease research will gather in San Diego to share new findings and evidence. Lilly looks forward to joining this collaborative effort to advance clinical science. Will you be there too? #TimeIsNowAD

Vascular and neurodegenerative changes often coexist in Alzheimer’s disease, interacting to contribute to cognitive decline. Dr. Pablo Martinez-Lage explores how protecting heart health through prevention and early management may also protect the brain.¹⁻⁴

Why do some individuals preserve cognitive function despite underlying Alzheimer’s disease pathology? Prof. Elisabeth Stögmann explains how cognitive resilience may delay onset and slow symptom progression. How can we promote cognitive resilience in healthcare systems?¹⁻²

On October 29th 2025, marking the International Day of Care and Support, we recognize the hidden economic burden of Alzheimer’s disease, where families and partners carry a substantial proportion of costs.¹ Let’s work towards fair recognition and sustainable care.

How can we raise more awareness for early-onset Alzheimer’s disease (AD), which tends to be overlooked due to its lower prevalence compared to late-onset AD? Watch Prof. Jiong Shi explain the distinctions between familial and sporadic forms of early-onset AD.¹⁻²

In your opinion, which action would best support the mental health of people with Alzheimer’s disease and their care partners?

On October 10th 2025, marking World Mental Health Day, how living with Alzheimer’s disease can affect the mental health of both, the people with the disease and their care partners.¹⁻⁴ Let’s help ensure they receive the mental health support they deserve!

At the 35ᵗʰ Alzheimer Europe Conference we discuss how education, specialist access, innovation and policy can improve timely Alzheimer’s disease diagnosis.¹ We think the #TimeIsNowAD to turn science into meaningful advances in Alzheimer’s disease care. #35AEC

Stigma and lack of awareness are barriers for timely detection.¹ At the 35th Alzheimer Europe Conference in Bologna, we ask: how can we reduce stigma and promote timely support? #35AEC #TimeIsNowAD

Only 5 days to go until the 35ᵗʰ Alzheimer Europe Conference in Bologna! Lilly, as a gold sponsor, is proud to be part of this important discussion on advancing Alzheimer’s disease care, policy, and research. See you there! #35AEC #TimeIsNowAD #AlzheimersAwareness

Thank you for all the valuable discussions during this World Alzheimer’s Month! Which topic will be your top priority for improving Alzheimer’s disease care?

Dr. Juan Fortea highlights how innovations in biomarkers can support timely and accurate diagnosis of Alzheimer’s disease. Yet, many barriers within the healthcare system still limit patient access to these tools.¹⁻⁴ How can we change this? #AlzheimersAwareness

Despite over 70% of specialists valuing diagnostic Alzheimer's disease biomarkers testing, fewer than 20% of patients receive one.¹ At Lilly, we believe the #TimeIsNowAD to support innovative diagnostic pathways that enable timely and accurate diagnosis. #WorldAlzheimersMonth

Dr. Ansgar Felbecker reminds us that an Alzheimer’s disease diagnosis affects patients and their care partners alike. Early diagnosis enables timely support and planning.¹,² How can we better support care partners? #AlzheimersAwareness #WorldAlzheimersMonth #TimeIsNowAD

An Alzheimer’s disease diagnosis affects the person living with it, and their loved ones. A timely diagnosis may allow care partners to prepare and seek support.¹,² At Lilly, we believe the #TimeIsNowAD to support care partners earlier in that journey. #WorldAlzheimersMonth